Management of Wide Complex Irregular Rhythm in WPW Syndrome

Immediate Management

For patients with Wolff-Parkinson-White syndrome who develop a wide complex irregular rhythm, intravenous procainamide or ibutilide is recommended as first-line pharmacological therapy if the patient is hemodynamically stable, according to the American College of Cardiology and European Heart Journal guidelines 1, 2
If unstable, immediate direct-current cardioversion is recommended, as per the American College of Cardiology and European Heart Journal guidelines 3, 4, 1

Intravenous ibutilide is a first-line pharmacological option for stable patients, as recommended by the American College of Cardiology and European Heart Journal guidelines 1, 2
Intravenous flecainide is an alternative option with a Class IIa recommendation, according to the American College of Cardiology guideline 1
Intravenous quinidine, disopyramide, or amiodarone are alternative options with a Class IIb recommendation, as per the American College of Cardiology and European Heart Journal guidelines 1, 2

The American College of Cardiology and European Heart Journal guidelines recommend never administering AV nodal blocking agents in WPW patients with pre-excited AF, as they can increase conduction through the accessory pathway and potentially precipitate ventricular fibrillation 4, 1
Specifically, beta-blockers, calcium channel blockers, and digoxin should be avoided, according to the American College of Cardiology, European Heart Journal, and other guidelines 4, 1, 5

After acute stabilization, catheter ablation of the accessory pathway is recommended as definitive treatment for symptomatic WPW patients, with a success rate of >95% and a complication rate of <1-2% in experienced centers, as per the American College of Cardiology, European Heart Journal, and other guidelines 1, 2, 5

Even after successful treatment of the acute episode, patients should be evaluated for definitive management with catheter ablation, as recommended by the American College of Cardiology guideline 1, 5
Ablation of the accessory pathway may not prevent recurrence of atrial fibrillation, especially in older patients, according to the European Heart Journal guideline 4, 2